Document Type
Article
Abstract
Introduction
For the approximately 7 million US individuals with diabetes who rely on insulin,1 the number of insulin prescriptions rose steadily in the decade before the COVID-19 pandemic.2 Reduced access to medical care and disruptions in supply related to the pandemic may have decreased access to insulin,3 with possible adverse consequences for diabetes control.4 Conversely, emergency Medicaid expansions that increased capacity for telemedicine services during the pandemic may have been associated with improved access to treatment.5 Therefore, this study aimed to assess whether changes to insulin prescription claims occurred during the COVID-19 pandemic.
Methods
In this cross-sectional study, we used pharmacy claims from a 10% random sample of patients with diabetes and at least 1 insulin claim from the US IQVIA Longitudinal Prescription Claims (LRx) data, a longitudinal dataset of patient prescriptions based on retail pharmacy data, to examine trends in prescription claims for insulin products. We counted the number of new and refill weekly insulin prescriptions between January 2019 and October 2020, except for the week surrounding the pandemic declaration (March 16, 2020) and weeks with national holidays because of expected outliers in prescription volume. Using an interrupted time series design with segmented regression analysis, we examined whether the pandemic changed the number of new and existing insulin prescription fills in adults and children. The regression model estimated weekly baseline prescription counts and their 95% CIs in 2019, the trend before the COVID-19 pandemic, and changes in trend immediately after the pandemic declaration and during the pandemic. Statistical significance was determined when the 95% CI did not include 0. All analyses were conducted using Stata statistical software, version 15.1 (StataCorp, LLC). The University of South Carolina’s Institutional Review Board deemed the study exempt from review and waived the requirement for informed consent because we used deidentified data. This report followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
Results
A total of 285 343 individuals met the study criteria; the mean (SD) age was 56.6 (18.5) years, and 148 110 (51.9%) were women. The weekly number of insulin prescriptions increased steadily before the pandemic (Figure). The baseline average count of all existing insulin prescriptions excluding weeks with major holidays in the first week of 2019 was estimated to be 17 037.5 (95% CI, 16 728.7-17 346.4). The estimated number of insulin prescriptions increased significantly every week before the pandemic by 11.0 (95% CI, 2.8-19.3). In the first week of the pandemic, the mean number of prescriptions decreased by −395.6 (95% CI, −933.5 to 142.4) per week, followed by a significant decrease of −55.3 (95% CI, −78.6 to −32.0) prescriptions per week during the pandemic vs before the pandemic. In addition, we found that the pandemic was associated with a significant decrease in the estimated mean number of weekly insulin prescriptions in the adult subgroup (−54.2; −76.5 to −31.8), but not in the pediatric and new prescription subgroups (Table).
Digital Object Identifier (DOI)
Publication Info
Published in JAMA Network Open, Volume 4, Issue 11, 2021, pages P27-52.
Rights
This is an open access article distributed under the terms of the CC-BY license, which permits unrestricted use, distribution, and reproduction in any medium. You are not required to obtain permission to reuse this article content, provided that you credit the author and journal.
APA Citation
Yunusa, I., Love, B. L., Cai, C., Hastings, T., Reeder, C. E., Blake, E. W., & Phillips, C. (2021). Trends in insulin prescribing for patients with diabetes during the COVID-19 pandemic in the US. JAMA Network Open, 4(11). https://doi.org/10.1001/jamanetworkopen.2021.32607